Phase 3 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to sign a written consent form after being fully informed about the study and its risks
- You have been diagnosed with focal epilepsy (a type of epilepsy that starts in one specific area of the brain) for at least 2 years, and have already tried at least 2 seizure medications at proper doses without achieving lasting seizure freedom
- You have been taking a steady dose of 1 to 3 approved seizure medications for at least one month before the study begins, and are able to continue this throughout the trial
- You are able to keep an accurate written diary of your seizures
Who may not be able to join:
- Your brain wave test (EEG) has shown a pattern that does not match focal epilepsy
- You have only ever had a specific mild type of focal seizure with no movement, seizures caused by psychological factors, seizures that start across the whole brain, or certain severe epilepsy conditions such as Lennox-Gastaut syndrome
- Your seizures are caused by drug or alcohol use, an active infection, a tumor, or certain other ongoing diseases affecting the brain or nervous system
- You have had a dangerous prolonged seizure, or seizures so frequent they could not be counted individually, in the 12 months before the study starts
- You have had brain surgery for epilepsy within the past year, or radiation-based brain treatment within the past 2 years
- You have any other health condition or personal situation that the study doctor believes could put you at risk or prevent you from following the study plan
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xenon Medical Director, Xenon Pharmaceuticals Inc.
Phone: 1-604-484-3300
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.